Trevi Therapeutics Stock Performance
| TRVI Stock | USD 6.47 0.14 2.12% |
On a scale of 0 to 100, Trevi Therapeutics holds a performance score of 11. The entity has a beta of -0.24, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Trevi Therapeutics are expected to decrease at a much lower rate. During the bear market, Trevi Therapeutics is likely to outperform the market. Please check Trevi Therapeutics' potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether Trevi Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Trevi Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Trevi Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 32.4 M | |
| Free Cash Flow | -38.3 M |
Trevi |
Trevi Therapeutics Relative Risk vs. Return Landscape
If you would invest 406.00 in Trevi Therapeutics on December 22, 2024 and sell it today you would earn a total of 241.00 from holding Trevi Therapeutics or generate 59.36% return on investment over 90 days. Trevi Therapeutics is currently generating 0.939% in daily expected returns and assumes 6.3853% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Trevi, and 82% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Trevi Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Trevi Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Trevi Therapeutics, and traders can use it to determine the average amount a Trevi Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1471
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TRVI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.39 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.94 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Trevi Therapeutics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Trevi Therapeutics by adding it to a well-diversified portfolio.
Trevi Therapeutics Fundamentals Growth
Trevi Stock prices reflect investors' perceptions of the future prospects and financial health of Trevi Therapeutics, and Trevi Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Trevi Stock performance.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | 516.04 M | ||||
| Shares Outstanding | 89.37 M | ||||
| Price To Book | 6.25 X | ||||
| EBITDA | (51.52 M) | ||||
| Cash And Equivalents | 77.86 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 1.03 M | ||||
| Debt To Equity | 0.21 % | ||||
| Book Value Per Share | 1.06 X | ||||
| Cash Flow From Operations | (38.26 M) | ||||
| Earnings Per Share | (0.46) X | ||||
| Total Asset | 110.9 M | ||||
| Retained Earnings | (287.05 M) | ||||
About Trevi Therapeutics Performance
By evaluating Trevi Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Trevi Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Trevi Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Trevi Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Trevi Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 23 people.Things to note about Trevi Therapeutics performance evaluation
Checking the ongoing alerts about Trevi Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Trevi Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Trevi Therapeutics is way too risky over 90 days horizon | |
| Trevi Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (47.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Trevi Therapeutics currently holds about 77.86 M in cash with (38.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Over 82.0% of the company shares are owned by institutional investors |
- Analyzing Trevi Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Trevi Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Trevi Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Trevi Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Trevi Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Trevi Therapeutics' stock. These opinions can provide insight into Trevi Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Trevi Stock analysis
When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |